Awards & Recognition

HKEX IPO (listed as 2257.HK, December 2025) — raised $293M

First major IPO of a generative-AI-native biotech company on a major Asian exchange. Industry-first milestone under Zhavoronkov's leadership.

Adjunct Professor of Artificial Intelligence

Academic recognition appointment at the preeminent US aging-research institute.

ISSCR Public Service Award (speaking/recognition)

Public-service recognition tied to ISSCR annual meeting speaking engagement; referenced in workspace profile.md §9.

Co-editor — *Artificial Intelligence for Healthy Longevity* (Springer)

Springer reference volume co-edited — functions as scientific-community recognition.

FDA Orphan Drug Designation — Insilico's first

First FDA orphan-drug designation for an AI-discovered candidate (for ISM001-055 in IPF). Regulatory recognition.

BioSpectrum Asia Entrepreneur of the Year Award 2022

Won for 'Applying Deep Learning Experience to Drug Discovery'. Citation noted: raised >$300M in multiple rounds, opened R&D centres in six countries/regions, nominated 7 preclinical candidates, and entered human clinical trials with an AI-discovered novel target + AI-designed novel molecule.

Sanofi AI drug discovery deal — up to $1.2B (biobucks)

Sanofi strategic partnership — significance benchmark and de facto recognition of Insilico's platform quality. Covered by Fierce Biotech, VentureBeat.

World's first clinical trial of a drug with both AI-discovered target and AI-designed molecule (ISM001-055 / rentosertib for IPF)

Nominated 2021 as preclinical candidate; entered Phase I trials 2022; Phase II 2023; *Nature Medicine* Phase IIa results 2025. Industry-first status itself functions as de facto recognition.

Forbes Contributor — AI, Longevity, Drug Discovery column

200+ articles since 2018. Forbes contributor status is editorially gated and serves as a recognition/credential.

Book — *The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy*

Trade-press book recognition establishing Zhavoronkov's early intellectual leadership in aging economics. Widely reviewed.

Biogerontology Research Foundation — Director

Director (as of 2024 per Wikipedia). Functions as a recognition/leadership appointment in the longevity research community.

Adjunct Professor

Academic recognition appointment.

CB Insights AI 100 — The most promising artificial intelligence startups

Insilico Medicine repeatedly named to the CB Insights AI 100 list — a widely cited ranking of the 100 most promising private AI companies globally. Repeat recognition across multiple years.

Forbes AI 50 / 30-50 / 50-Over-50 — Insilico coverage

Insilico Medicine featured in Forbes AI-company rankings / spotlight coverage; see Aayushi Pratap Forbes story (2021): 'This Biotech Startup Just Raised $255 Million To Make Its AI-Designed Drug A Reality'.

Institute for the Study of Aging / SENS Foundation recognition

Zhavoronkov's Biogerontology Research Foundation work has been recognized by the ISA and SENS Foundation communities. (Workspace profile.md §9.)

Drug Discovery Trends — '10 pioneering companies implementing AI in drug discovery'

Insilico named pioneering AI-drug-discovery company.

Nature editorial recognition — 'AI-powered drug discovery captures pharma interest'

Early editorial recognition of Insilico/Zhavoronkov in Nature Biotechnology — foundational credibility signal.

Forbes 30 Under 30 — Healthcare / Science

Time 100 Most Influential People in AI / Health

Forbes '50 Over 50'